Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Richardson, Paul G., Siegel, David, Baz, Rachid, Kelley, Susan L., Munshi, Nikhil C., Laubach, Jacob, Sullivan, Daniel, Alsina, Melissa, Schlossman, Robert, Ghobrial, Irene M., Doss, Deborah, Loughney, Nora, McBride, Laura, Bilotti, Elizabeth, Anand, Palka, Nardelli, Lisa, Wear, Sandra, Larkins, Gail, Chen, Min, Zaki, Mohamad H., Jacques, Christian, Anderson, Kenneth C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2013
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123324/
https://ncbi.nlm.nih.gov/pubmed/23243282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-450742
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki